Business Context and Reporting Period
Company: Microbot Medical Inc. (MBOT)
Filing Type: Form 8-K (Current Report)
Date of Report: May 14, 2026
Reporting Period: First Quarter 2026 and Second Quarter 2026 (Year-to-Date)
Business Focus: The filing concerns the commercialization of the LIBERTY® Endovascular Robotic System.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a qualitative disclosure of revenue generation trends rather than a quantitative financial statement.
- Revenue Status: The Company recorded revenue from the limited market release of the LIBERTY System in Q1 2026.
- Q2 2026 Performance: Revenue for the second quarter of 2026 has already exceeded Q1 2026 revenue.
- Drivers: Increased revenue is attributed to the transition to a full market release and accelerating utilization and adoption across multiple sales territories.
Material Changes Versus Prior Period
Commercial Transition: The Company has transitioned from a limited market release to a full market release of the LIBERTY System.
Revenue Growth: There is a material increase in revenue momentum, with Q2 2026 revenue surpassing Q1 2026 revenue within the same fiscal year.
Guidance, Outlook, and Risks
Outlook: Management indicates that utilization and adoption of the LIBERTY System are accelerating across multiple sales territories.
Forward-Looking Statements: The filing contains forward-looking statements regarding beliefs, plans, expectations, and regulatory milestones. The Company explicitly states that actual results could differ from projections due to numerous factors and assumes no obligation to update these statements except as required by law.
Risks: Investors are directed to consult risk factors disclosed in other SEC filings for details on potential variances from projected results.
Key Facts for Investor Verification
- Verify the specific dollar amounts of Q1 2026 and Q2 2026 revenue in the Company's upcoming quarterly earnings report (Form 10-Q).
- Confirm the timeline and scope of the "full market release" of the LIBERTY System.
- Review the press release (Exhibit 99.1) referenced in this filing for additional qualitative details on sales territory expansion.
- Assess the Company's cash burn rate and liquidity position in subsequent filings, as this 8-K does not disclose financial position metrics.